Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-024014
Filing Date
2025-08-14
Accepted
2025-08-14 16:07:33
Documents
64
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 702848
2 EX-4.4 ex4-4.htm EX-4.4 31708
3 EX-31.1 ex31-1.htm EX-31.1 11453
4 EX-31.2 ex31-2.htm EX-31.2 11504
5 EX-32.1 ex32-1.htm EX-32.1 8462
6 GRAPHIC form10-q_001.jpg GRAPHIC 7011
  Complete submission text file 0001641172-25-024014.txt   4018965

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE mtnb-20250630.xsd EX-101.SCH 30979
8 XBRL CALCULATION FILE mtnb-20250630_cal.xml EX-101.CAL 48894
9 XBRL DEFINITION FILE mtnb-20250630_def.xml EX-101.DEF 112571
10 XBRL LABEL FILE mtnb-20250630_lab.xml EX-101.LAB 306898
11 XBRL PRESENTATION FILE mtnb-20250630_pre.xml EX-101.PRE 242337
66 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 472797
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

EIN.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38022 | Film No.: 251218909
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)